Unique

our projects

The project portfolio of Xlife Sciences AG is based on four pillars: technology platforms, biotech and therapies, medical technology and artificial intelligence. Our co-investors benefit from our unique selling proposition. In addition, our broad project portfolio offers adequate risk diversification.

Axenoll Life Sciences AG

Medical Technology

Axenoll Life Sciences AG is revolutionising 3D bioprinting through "Axenoll® 3D printing for life". Axenoll Life Sciences AG owns the global licensing rights for cellular and molecular 3D bioprinting in the context of clean room research & development, production and marketing based on the patented Exentis 3D Mass Customization®, the 3D screen printing technology made available by Exentis.

Learn more

Laxxon Medical AG

Medical Technology

Laxxon Medical AG owns the exclusive global rights for development, production, and commercialization of an innovative new drug delivery system for the controlled release of pharmaceutical actives. This new process is based on a patented 3D printing process.

Learn more

saniva diagnostics GmbH

Medical Technology

saniva diagnostics GmbH develops a screening instrument (hardware and software), based on the Falling-Stick-Test.

Learn more

Vitruvia AG

Medical Technology

Vitruvia AG is Europe‘s foremost technology company in the healthcare sector of the circular economy. As a supplier of innovative circular systems for highly complex medical devices, particularly in robot-assisted surgery, Vitruvia AG supports hospitals in creating a secure future.

Learn more

Sign up for our newsletter

We regularly report on the business development of Xlife Sciences AG and our project companies.